Kurv Yield Prem Strategy Tesla ETF (TSLP)
| Assets | $20.96M |
| Expense Ratio | 1.00% |
| PE Ratio | 120.49 |
| Shares Out | 1.13M |
| Dividend (ttm) | $8.40 |
| Dividend Yield | 41.25% |
| Ex-Dividend Date | Aug 6, 2025 |
| Payout Ratio | 4,969.62% |
| 1-Year Return | -2.67% |
| Volume | 12,698 |
| Open | 20.47 |
| Previous Close | 20.54 |
| Day's Range | 20.37 - 20.81 |
| 52-Week Low | 15.36 |
| 52-Week High | 34.29 |
| Beta | n/a |
| Holdings | 10 |
| Inception Date | Oct 27, 2023 |
About TSLP
Fund Home PageThe Kurv Yield Prem Strategy Tesla ETF (TSLP) is an exchange-traded fund that mostly invests in consumer discretionary equity. The fund seeks to provide current income and capped gains on the Tesla stock (TSLA) through a synthetic covered call strategy, collateralized by cash and short-term fixed-income instruments. The actively managed fund uses both standardized exchange-traded and FLEX options. TSLP was launched on Oct 27, 2023 and is issued by Kurv.
Top 10 Holdings
100.00% of assets| Name | Symbol | Weight |
|---|---|---|
| United States Treasury Bills 0% | B.0 03.19.26 | 43.57% |
| United States Treasury Bills 0% | B.0 09.18.25 | 29.15% |
| United States Treasury Bills 0% | B.0 12.26.25 | 28.83% |
| Tsla 09/19/2025 330 C | n/a | 16.49% |
| Cash Offset | n/a | 3.98% |
| Fidelity Government Portfolio | FIGXX | 1.19% |
| TSLA US 08/15/25 P250 | n/a | 0.38% |
| DEPOSITS WITH BROKER FOR SHORT POSITIONS | n/a | -0.01% |
| Tsla 08/15/2025 325 C | n/a | -6.34% |
| Tsla 09/19/2025 330 P | n/a | -17.25% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Aug 6, 2025 | $0.450 | Aug 7, 2025 |
| Jul 2, 2025 | $0.450 | Jul 3, 2025 |
| Jun 4, 2025 | $0.500 | Jun 5, 2025 |
| May 7, 2025 | $0.550 | May 8, 2025 |
| Apr 2, 2025 | $0.550 | Apr 3, 2025 |
| Mar 5, 2025 | $0.700 | Mar 6, 2025 |
News
Kurv Investment Management Completes Reorganization of Yield Premium Suite to Proprietary Trust
SAN FRANCISCO--(BUSINESS WIRE)--Kurv Investment Management, an ETF provider of tax-efficient, institutional-grade investment strategies, announces the successful reorganization of its Yield Premium Su...
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Soci...